2500 Participants Needed

Observational Study for Autoimmune Hepatitis

(CaNAL Trial)

Recruiting at 15 trial locations
SR
KT
Overseen ByKattleya Tirona, BA, CCRP
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University Health Network, Toronto
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial focuses on understanding rare liver diseases such as Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH). It does not test new drugs or treatments but observes patients over time to gather important data. The goal is to learn more about how these diseases progress and identify factors that might influence outcomes, such as the need for a liver transplant or the risk of liver cancer. This information can help doctors predict and treat these conditions earlier. Individuals diagnosed with PBC or AIH might be suitable for this study. As an unphased study, it offers patients the chance to contribute to valuable research that could lead to earlier diagnosis and better management of their condition.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to gather crucial data on autoimmune liver diseases by observing patients closely during their regular care. Unlike standard treatments, which focus on alleviating symptoms or slowing disease progression, this observational approach will help identify patterns, outcomes, and potential triggers in real-world settings. This can lead to a deeper understanding of the disease, potentially paving the way for more effective, targeted treatments in the future.

Who Is on the Research Team?

BH

Bettina Hansen, PhD

Principal Investigator

University Health Network, Toronto General Hospital

AM

Andrew Mason, MD

Principal Investigator

University of Alberta

Are You a Good Fit for This Trial?

Inclusion Criteria

Diagnosis of Primary Biliary Cholangitis and/or Autoimmune Hepatitis

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Observational

Participants are observed through their regular standard of care visits

6 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Observational
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: ObservationalExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials
1,555
Recruited
526,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security